Avenacy’s strategic move to bring Dr. Patrick Soon-Shiong on board as a co-founder signals a significant step forward for the company in addressing the critical shortages of injectable medications in the U.S. market. With Soon-Shiong’s extensive track record and NantCapital’s backing, Avenacy is well-positioned to expand its portfolio and cement its reputation as a key player in the specialty pharmaceutical industry. The combined leadership of Soon-Shiong and Yordon, both of whom have a history of building successful pharmaceutical ventures, bodes well for Avenacy’s future growth and its mission to deliver safe, high-quality medications to healthcare providers nationwide.